Publications by authors named "Zhuoye Chen"
QIM25-232: Extracellular Vesicles Evade the Antiangiogenic Effect of Bevacizumab in Ovarian Cancer.
J Natl Compr Canc Netw
March 2025
CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer.
Drug Resist Updat
November 2024
Article Synopsis
- Ovarian cancer, the deadliest gynecological cancer, faces major treatment obstacles, particularly with PARP inhibitors (PARPi) for BRCA1/2-mutated tumors, as resistance to these drugs is a significant challenge.
- An experiment developed a PARPi-resistant cell line (A2780-OlaR), revealing increased levels of CYP1B1, and demonstrated that manipulating its expression affected responses to Olaparib, the PARP inhibitor.
- The study concludes that CYP1B1 plays a crucial role in PARPi resistance, showing how chromatin accessibility impacts drug effectiveness and suggesting new strategies to fight ovarian cancer.
GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells.
Curr Cancer Drug Targets
August 2024
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) are now widely used in BRCA1/2 mutation or homologous recombination (HR) deficiency ovarian cancer but have limited efficacy in HR-proficient patients. GPX4 is a key regulator of ferroptosis and has been proven to be associated with multiple drug sensitivities. As a molecule that regulates the sensitivity of multiple drugs, the relationship between GPX4 and the efficacy of PARPi in HR-proficient ovarian cancer has not been elucidated.
View Article and Find Full Text PDFCircular RNAs (circRNAs) are critical regulators in the occurrence and development of numerous cancers, in which abnormal autophagy plays a key role. However, the potential involvement of circRNAs in autophagy is largely unknown. Here, we identified the overexpression of circTICRR, a circular RNA, in cervical cancer.
View Article and Find Full Text PDF